
News briefing: SpringWorks, Jazz exchange $35M and PTSD drug; Dr. Reddy's says cyberattack was ransomware
Jazz Pharmaceuticals is grabbing an ex-Pfizer drug to beef up its mid-stage neuroscience portfolio, paying SpringWorks $35 million in cash for a new med for post-traumatic stress disorder.
PF-04457845 is a FAAH inhibitor that was originally tested for osteoarthritis. But SpringWorks — and now Jazz — has potential to address multiple core symptoms of PTSD, including fear extinction, anxiety and disrupted sleep architecture.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.